Artivion Secures FDA Approval for NEXUS Aortic Arch System [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
Developed in partnership with Endospan Ltd., this innovative device targets aortic arch disease, one of the most challenging areas in cardiovascular care. The FDA approval gives Artivion the right to exercise its option to acquire Endospan Ltd. within a 90-day window from the date of approval. In preparation for this possibility, the company has secured a $150 million delayed draw term loan to help finance the potential acquisition. Per management, the earlier-than-expected FDA approval of NEXUS is a major and encouraging development for patients with aortic arch disease, as well as for Endospan and Artivion. Results from the TRIOMPHE trial have highlighted the technology's strong clinical benefits and expressed pride in AORT's role in supporting Endospan throughout the process. The company has arranged financing to enable a potential acquisition and is working through its decision on exercising that option, with plans to share updates with shareholders in the near future. Likel
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates [Yahoo! Finance]Yahoo! Finance
- 1 Stock Under $50 to Own for Decades and 2 We Avoid [Yahoo! Finance]Yahoo! Finance
- Artivion (AORT) was upgraded by LADENBURG THALM/SH SH from "neutral" to "buy". They now have a $42.00 price target on the stock.MarketBeat
- Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know [Yahoo! Finance]Yahoo! Finance
- Artivion (AORT) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $58.00 price target on the stock.MarketBeat
AORT
Earnings
- 2/12/26 - Beat
AORT
Sec Filings
- 4/1/26 - Form ARS
- 4/1/26 - Form DEFA14A
- 4/1/26 - Form DEF
- AORT's page on the SEC website